Australia - English - Department of Health (Therapeutic Goods Administration)

one dental pty ltd - 31828 - dental x-ray system beam alignment device - a mechanical device that is used to support and position dental x-ray film and to serve as a guide for proper physical alignment of the x-ray tube with the positioned dental x-ray film during dental x-ray imaging procedures. depending on the device design, it can be used as a guide for either intraoral or extraoral dental x-ray systems.

Australia - English - Department of Health (Therapeutic Goods Administration)

3d printing studios pty ltd - 57940 - nasopharyngeal swab - for the collection of specimens from a patient to be transported to a laboratory for the purpose of in vitro diagnostic examination. nasopharyngeal swabs are used for the detection of respiratory viruses such as covid-19, rsv, influenza virus a & b or parainfluenza virus. the swabs are 3d printed in a range of sizes which are comfortable for different kinds of patients in pcr compliant nylon 12

United States - English - NLM (National Library of Medicine)

advantage sales and marketing - coal tar (unii: r533eso2ec) (coal tar - unii:r533eso2ec) - coal tar .55 g in 100 g

Australia - English - Department of Health (Therapeutic Goods Administration)

synalinx pty ltd - 34917 - catheter, urological, foley - two-way foley catheter is made up of natural rubber latex intended for routine and post-operative drainage of urine from bladder. the three-way foley catheter is made up of natural rubber latex intended for routine and post-operative drainage of urine and also for irrigation of bladder.

Australia - English - Department of Health (Therapeutic Goods Administration)

synalinx pty ltd - ct701 - infectious disease ivds - the kit is a rapid chromatographic immunoassay for the qualitative detection of antigens specific to sars-cov-2 in nasal/nasopharyngeal swabs containing samples collected from a human nasopharynx. this product provides only a preliminary test result. the test is recommended for administration by qualified healthcare workers as an aid for rapid differential diagnosis of sars-cov-2 infection in patients with associated clinical symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - perindopril erbumine, quantity: 4 mg; indapamide hemihydrate, quantity: 1.25 mg (equivalent: indapamide, qty 1.22 mg) - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hydrophobic colloidal silica anhydrous; magnesium stearate - treatment of hypertension. treatment should not be initiated with this combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml; hepatitis a virus antigen, quantity: 720 elisa unit/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; aluminium phosphate; polysorbate 20; water for injections; neomycin sulfate; monobasic sodium phosphate; trometamol; sodium chloride; dibasic sodium phosphate heptahydrate; formaldehyde solution; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years. twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - hepatitis b surface antigen recombinant, quantity: 20 microgram/ml; hepatitis a virus antigen, quantity: 720 elisa unit/ml - injection, suspension - excipient ingredients: trometamol; aluminium hydroxide hydrate; sodium chloride; polysorbate 20; neomycin sulfate; water for injections; formaldehyde solution; aluminium phosphate; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate; acetic acid; leucine; phenylalanine; methionine; lysine hydrochloride; isoleucine; valine; histidine; threonine; tryptophan; alanine; arginine; proline; tyrosine; serine; sodium acetate; dibasic potassium phosphate; magnesium chloride hexahydrate; glycine - twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years. twinrix (720/20) is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults and children from 1 year of age. twinrix junior (360/10) is indicated for use in children aged 1 to 15 years.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 10 microgram/ml - injection, suspension - excipient ingredients: aluminium; borax; sodium chloride; water for injections - h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who ar at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 5 microgram - injection, suspension - excipient ingredients: borax; water for injections; sodium chloride; aluminium - for use in the immunisation against infection caused by all known subtypes of hepatitis b virus. indications as at 17 november 2000: h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who are at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.